Scott joined Foghorn in 2018 to lead new product planning and guide a range of business operations initiatives. He currently serves as a vice president and program lead. Scott has over 15 years of experience in program, disease and portfolio strategy across multiple therapeutic categories and carries a passion for translating scientific advancement into new medicines.
Before joining Foghorn, Scott held a variety of strategic and operational roles across all phases of development within the multiple sclerosis and neurodegeneration therapeutic areas at Biogen. Prior to Biogen, Scott was a strategy consultant at Leerink Partners where he advised biopharmaceutical clients on program development, licensing, and therapeutic area strategy. He started his career at Altus Pharmaceuticals in corporate and commercial development.
Scott holds an MS in biotechnology from Northwestern University and a BS in zoology from Miami University (OH).